Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 215 participants.
Also called NCT03026933
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 215 participants
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
- Registry
-
NCT03026933
-
- Other papers using this trial's data
- Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT03026933. Randomized; double masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2016-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled
- Acronym
- ROMANTIC
- Condition
- Dyslipidemias
- Intervention (Drug)
- KI1107 4 Capsules, QD
- Intervention (Drug)
- Rosuvastatin Calcium 20 MG, QD
- Lead sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct03026933- Content hash
28c8923641a6993337916d205100009ae34e3bc0f4bd57e4fe903bc9bb09fd78